Get the app
US › Healthcare

Upstream Bio, Inc. (UPB)

US · Healthcare · Biotechnology

$2.76-18.10%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$773,000
Revenue YoY
-17.5%
Net profit
$-39.7M
EPS
$-0.73
EPS estimate
$-0.78
Net margin
-5,136.1%

EPS came in at -0.73 against a street estimate of -0.78 — a beat of 6.4%.

Key statistics

Market cap
$194.4M
Forward P/E
0.0
P/B
1.05
Book value
$4.95
EPS (TTM)
$-2.45
52-week high
$33.68
52-week low
$3.29
50-day MA
$6.03
200-day MA
$11.08
Beta
1.39

Analyst view

Analysts rate Upstream Bio, Inc. a buy (6 buy, 2 hold, 0 sell out of 8) with an average price target of $31.14.

Shareholding

Insiders
14.78%
Institutions
92.44%

Largest institutional holders

FundStake
FMR Inc14.90%
Orbimed Advisors LLC10.40%
NORGES BANK6.88%
BlackRock Inc6.85%
Decheng Capital LLC4.97%
Enavate Sciences GP, LLC4.49%
Vanguard Capital Management, LLC3.43%
Millennium Management LLC2.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Upstream Bio, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.